Teleflex (NYSE:TFX) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Teleflex (NYSE:TFX) had its target price lifted by investment analysts at Royal Bank Of Canada from $115.00 to $125.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “sector perform” rating on the medical technology company’s stock. Royal Bank Of Canada’s price target suggests a potential upside of 2.47% from the company’s current price.

TFX has been the topic of several other research reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Teleflex in a research report on Monday, December 29th. Wall Street Zen lowered shares of Teleflex from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Needham & Company LLC lifted their target price on shares of Teleflex from $138.00 to $147.00 and gave the company a “buy” rating in a report on Thursday. Truist Financial upped their price target on shares of Teleflex from $120.00 to $135.00 and gave the company a “hold” rating in a research report on Thursday, December 18th. Finally, Wells Fargo & Company lifted their price objective on shares of Teleflex from $116.00 to $130.00 and gave the company an “equal weight” rating in a research note on Friday. Two analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $140.63.

Teleflex Stock Up 2.5%

Shares of NYSE TFX traded up $2.97 during mid-day trading on Friday, reaching $121.99. The company had a trading volume of 677,505 shares, compared to its average volume of 1,059,447. The firm has a 50 day simple moving average of $111.34 and a two-hundred day simple moving average of $118.68. Teleflex has a 52-week low of $100.18 and a 52-week high of $143.32. The company has a current ratio of 2.57, a quick ratio of 1.53 and a debt-to-equity ratio of 0.67. The stock has a market cap of $5.39 billion, a P/E ratio of -16.62, a PEG ratio of 1.46 and a beta of 0.92.

Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, February 26th. The medical technology company reported $1.93 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.73 by ($1.80). Teleflex had a negative net margin of 10.28% and a positive return on equity of 15.64%. The company had revenue of $569.00 million during the quarter, compared to analyst estimates of $912.57 million. During the same quarter in the prior year, the company earned $3.89 EPS. The business’s revenue was down 28.5% on a year-over-year basis. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. Sell-side analysts predict that Teleflex will post 13.98 earnings per share for the current year.

Institutional Investors Weigh In On Teleflex

Institutional investors have recently added to or reduced their stakes in the business. Empowered Funds LLC boosted its stake in shares of Teleflex by 15.8% in the first quarter. Empowered Funds LLC now owns 1,684 shares of the medical technology company’s stock valued at $233,000 after buying an additional 230 shares in the last quarter. Jane Street Group LLC lifted its holdings in Teleflex by 42.6% in the first quarter. Jane Street Group LLC now owns 6,343 shares of the medical technology company’s stock valued at $877,000 after acquiring an additional 1,895 shares during the period. Teacher Retirement System of Texas boosted its position in shares of Teleflex by 31.5% during the 2nd quarter. Teacher Retirement System of Texas now owns 11,819 shares of the medical technology company’s stock worth $1,399,000 after purchasing an additional 2,831 shares in the last quarter. Arkadios Wealth Advisors grew its stake in shares of Teleflex by 61.8% during the 2nd quarter. Arkadios Wealth Advisors now owns 5,403 shares of the medical technology company’s stock worth $639,000 after purchasing an additional 2,064 shares during the period. Finally, Strs Ohio grew its stake in shares of Teleflex by 4.9% during the 2nd quarter. Strs Ohio now owns 23,067 shares of the medical technology company’s stock worth $2,730,000 after purchasing an additional 1,067 shares during the period. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Trending Headlines about Teleflex

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Board approved a multi‑year restructuring to support planned divestitures and portfolio reshaping; the plan is intended to lower costs and streamline the business, which investors may view as a credible path to restore growth and margins. Teleflex Launches Multi-Year Restructuring to Support Divestitures
• Positive Sentiment: Board declared a quarterly cash dividend of $0.34 per share (payable March 31; record March 6), providing income support and signaling confidence in cash generation through the transition. Teleflex Announces Quarterly Dividend
• Neutral Sentiment: Company released the earnings presentation and held the earnings call — these contain management’s rationale, timing for divestitures, and details on cost actions; useful for investors who want to vet assumptions behind guidance. Teleflex Incorporated 2025 Q4 – Results – Earnings Call Presentation
• Negative Sentiment: Q4 results missed materially — GAAP/adjusted EPS and revenue both fell short (quarterly revenue ~$569M, down ~28.5% YoY) and margins compressed; the miss reflects weak continuing operations and hit near‑term earnings power. Teleflex (TFX) Q4 Earnings and Revenues Miss Estimates
• Negative Sentiment: Management cut FY‑2026 outlook sharply (EPS guidance $6.25–$6.55 vs. consensus ~15.18; revenue guide ~ $2.3B vs. est ~$3.7B), signaling a major reset in expected results — the guidance downgrade is the primary driver of near‑term downside risk. Teleflex Reports 2025 Financial Results and Full Year 2026 Outlook

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.